Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMEDY-RCC: Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced RCC
NCT07611825Phase 2Recruiting
- Sponsor
- Jinling Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, ipilimumab and clostridium butyricum in renal cell carcinoma (RCC), sponsored by Jinling Hospital. Primary endpoint: Objective Response Rate up to 2 years. Started Jun 2026; status: recruiting.
02
Drugs
toripalimabipilimumabclostridium butyricum
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07611825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07611825.